Alexion acquisition to be examined by U.K. regulators

British regulatory authorities have opened an inquiry into AstraZeneca’s proposed $39 billion acquisition of Boston’s Alexion Pharmaceuticals Inc. (Nasdaq: ALXN), on the basis that the transaction could negatively affect competition.